CONSOLIDATED EDISON INC — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that CONSOLIDATED EDISON INC filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $16.92B | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $15.26B | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | $14.66B | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | $15.67B | Feb 20, 2025 |
| FY2023 | Dec 31, 2021 | $13.68B | Feb 15, 2024 |
| FY2022 | Dec 31, 2020 | $12.25B | Feb 16, 2023 |
| FY2021 | Dec 31, 2019 | $12.57B | Feb 17, 2022 |
| FY2020 | Dec 31, 2018 | $12.34B | Feb 18, 2021 |
| FY2020 | Dec 31, 2017 | $12.03B | Feb 18, 2021 |
| FY2018 | Dec 31, 2016 | $12.08B | Feb 21, 2019 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $17.05B | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $15.47B | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | $14.48B | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | $15.46B | Feb 20, 2025 |
| FY2023 | Dec 31, 2021 | $13.46B | Feb 15, 2024 |
| FY2022 | Dec 31, 2020 | $12.03B | Feb 16, 2023 |
| FY2021 | Dec 31, 2019 | $12.14B | Feb 17, 2022 |
| FY2020 | Dec 31, 2018 | $11.93B | Feb 18, 2021 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.02B | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $1.82B | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | $2.52B | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | $1.66B | Feb 20, 2025 |
| FY2023 | Dec 31, 2021 | $1.35B | Feb 15, 2024 |
| FY2022 | Dec 31, 2020 | $1.10B | Feb 16, 2023 |
| FY2021 | Dec 31, 2019 | $1.34B | Feb 17, 2022 |
| FY2020 | Dec 31, 2018 | $1.38B | Feb 18, 2021 |
| FY2020 | Dec 31, 2017 | $1.53B | Feb 18, 2021 |
| FY2018 | Dec 31, 2016 | $1.25B | Feb 21, 2019 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.94B | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $2.67B | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | $3.20B | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | $2.62B | Feb 20, 2025 |
| FY2023 | Dec 31, 2021 | $2.83B | Feb 15, 2024 |
| FY2022 | Dec 31, 2020 | $2.65B | Feb 16, 2023 |
| FY2021 | Dec 31, 2019 | $2.68B | Feb 17, 2022 |
| FY2020 | Dec 31, 2018 | $2.66B | Feb 18, 2021 |
| FY2019 | Dec 31, 2017 | $2.77B | Feb 20, 2020 |
| FY2018 | Dec 31, 2016 | $2.78B | Feb 21, 2019 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | $27.00M | Feb 16, 2023 |
| FY2022 | Dec 31, 2021 | $25.00M | Feb 16, 2023 |
| FY2022 | Dec 31, 2020 | $24.00M | Feb 16, 2023 |
| FY2021 | Dec 31, 2019 | $24.00M | Feb 17, 2022 |
| FY2020 | Dec 31, 2018 | $24.00M | Feb 18, 2021 |
| FY2019 | Dec 31, 2017 | $24.00M | Feb 20, 2020 |
| FY2018 | Dec 31, 2016 | $24.00M | Feb 21, 2019 |
| FY2017 | Dec 31, 2015 | $23.00M | Feb 15, 2018 |
| FY2016 | Dec 31, 2014 | $22.00M | Feb 16, 2017 |
| FY2015 | Dec 31, 2013 | $18.00M | Feb 18, 2016 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.80B | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $3.61B | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | $2.16B | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | $3.94B | Feb 20, 2025 |
| FY2023 | Dec 31, 2021 | $2.73B | Feb 15, 2024 |
| FY2022 | Dec 31, 2020 | $2.20B | Feb 16, 2023 |
| FY2021 | Dec 31, 2019 | $3.13B | Feb 17, 2022 |
| FY2020 | Dec 31, 2018 | $2.70B | Feb 18, 2021 |
| FY2019 | Dec 31, 2017 | $3.37B | Feb 20, 2020 |
| FY2018 | Dec 31, 2016 | $3.46B | Feb 21, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | $4.47B | Feb 16, 2023 |
| FY2022 | Dec 31, 2021 | $3.96B | Feb 16, 2023 |
| FY2022 | Dec 31, 2020 | $4.09B | Feb 16, 2023 |
| FY2021 | Dec 31, 2019 | $3.68B | Feb 17, 2022 |
| FY2020 | Dec 31, 2018 | $5.25B | Feb 18, 2021 |
| FY2019 | Dec 31, 2017 | $3.61B | Feb 20, 2020 |
| FY2018 | Dec 31, 2016 | $5.24B | Feb 21, 2019 |
| FY2017 | Dec 31, 2015 | $492.00M | Feb 15, 2018 |
| FY2016 | Dec 31, 2014 | $180.00M | Feb 16, 2017 |
| FY2015 | Dec 31, 2013 | $199.00M | Feb 18, 2016 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $74.60B | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $70.56B | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | $66.33B | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | $69.07B | Feb 20, 2025 |
| FY2023 | Dec 31, 2021 | $63.12B | Feb 15, 2024 |
| FY2022 | Dec 31, 2020 | $62.90B | Feb 16, 2023 |
| FY2021 | Dec 31, 2019 | $58.08B | Feb 17, 2022 |
| FY2020 | Dec 31, 2018 | $53.92B | Feb 18, 2021 |
| FY2019 | Dec 31, 2017 | $48.11B | Feb 20, 2020 |
| FY2018 | Dec 31, 2016 | $48.26B | Feb 21, 2019 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $24.19B | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $21.96B | Feb 19, 2026 |
| FY2023 | Dec 31, 2023 | $21.16B | Feb 15, 2024 |
| FY2023 | Dec 31, 2022 | $20.69B | Feb 15, 2024 |
| FY2022 | Dec 31, 2021 | $20.04B | Feb 16, 2023 |
| FY2021 | Dec 31, 2020 | $18.85B | Feb 17, 2022 |
| FY2020 | Dec 31, 2019 | $18.02B | Feb 18, 2021 |
| FY2019 | Dec 31, 2018 | $16.73B | Feb 20, 2020 |
| FY2018 | Dec 31, 2017 | $15.42B | Feb 21, 2019 |
| FY2017 | Dec 31, 2016 | $14.30B | Feb 15, 2018 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $406.00M | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $408.00M | Feb 19, 2026 |
| FY2024 | Dec 31, 2023 | $408.00M | Feb 20, 2025 |
| FY2023 | Dec 31, 2022 | $408.00M | Feb 15, 2024 |
| FY2022 | Dec 31, 2021 | $439.00M | Feb 16, 2023 |
| FY2021 | Dec 31, 2020 | $446.00M | Feb 17, 2022 |
| FY2020 | Dec 31, 2019 | $446.00M | Feb 18, 2021 |
| FY2019 | Dec 31, 2018 | $440.00M | Feb 20, 2020 |
| FY2018 | Dec 31, 2017 | $428.00M | Feb 21, 2019 |
| FY2017 | Dec 31, 2016 | $428.00M | Feb 15, 2018 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $14.86B | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $14.05B | Feb 19, 2026 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.63B | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $1.32B | Feb 19, 2026 |
| FY2024 | Dec 31, 2023 | $1.19B | Feb 20, 2025 |
| FY2023 | Dec 31, 2022 | $1.28B | Feb 15, 2024 |
| FY2022 | Dec 31, 2021 | $992.00M | Feb 16, 2023 |
| FY2021 | Dec 31, 2020 | $1.27B | Feb 17, 2022 |
| FY2020 | Dec 31, 2019 | $981.00M | Feb 18, 2021 |
| FY2019 | Dec 31, 2018 | $895.00M | Feb 20, 2020 |
| FY2018 | Dec 31, 2017 | $797.00M | Feb 21, 2019 |
| FY2017 | Dec 31, 2016 | $776.00M | Feb 15, 2018 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $25.80B | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $24.71B | Feb 19, 2026 |
| FY2024 | Dec 31, 2023 | $22.24B | Feb 20, 2025 |
| FY2023 | Dec 31, 2022 | $23.44B | Feb 15, 2024 |
| FY2022 | Dec 31, 2021 | $23.04B | Feb 16, 2023 |
| FY2021 | Dec 31, 2020 | $22.35B | Feb 17, 2022 |
| FY2020 | Dec 31, 2019 | $19.97B | Feb 18, 2021 |
| FY2019 | Dec 31, 2018 | $18.15B | Feb 20, 2020 |
| FY2018 | Dec 31, 2017 | $16.03B | Feb 21, 2019 |
| FY2017 | Dec 31, 2016 | $14.77B | Feb 15, 2018 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 5 | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | 5 | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | 7 | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | 4 | Feb 20, 2025 |
| FY2023 | Dec 31, 2021 | 3 | Feb 15, 2024 |
| FY2022 | Dec 31, 2020 | 3 | Feb 16, 2023 |
| FY2021 | Dec 31, 2019 | 4 | Feb 17, 2022 |
| FY2020 | Dec 31, 2018 | 4 | Feb 18, 2021 |
| FY2019 | Dec 31, 2017 | 4 | Feb 20, 2020 |
| FY2018 | Dec 31, 2016 | 4 | Feb 21, 2019 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 5 | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | 5 | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | 7 | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | 4 | Feb 20, 2025 |
| FY2023 | Dec 31, 2021 | 3 | Feb 15, 2024 |
| FY2022 | Dec 31, 2020 | 3 | Feb 16, 2023 |
| FY2021 | Dec 31, 2019 | 4 | Feb 17, 2022 |
| FY2020 | Dec 31, 2018 | 4 | Feb 18, 2021 |
| FY2019 | Dec 31, 2017 | 4 | Feb 20, 2020 |
| FY2018 | Dec 31, 2016 | 4 | Feb 21, 2019 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 361.12M | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | 346.60M | Feb 19, 2026 |
| FY2024 | Dec 31, 2023 | 345.42M | Feb 20, 2025 |
| FY2023 | Dec 31, 2022 | 354.96M | Feb 15, 2024 |
| FY2022 | Dec 31, 2021 | 353.98M | Feb 16, 2023 |
| FY2021 | Dec 31, 2020 | 342.30M | Feb 17, 2022 |
| FY2020 | Dec 31, 2019 | 332.63M | Feb 18, 2021 |
| FY2019 | Dec 31, 2018 | 320.96M | Feb 20, 2020 |
| FY2015 | Dec 31, 2015 | 21.98M | Feb 18, 2016 |
| FY2015 | Dec 31, 2014 | 21.98M | Feb 18, 2016 |
Dividends Paid
Cash dividends distributed to common shareholders during the period. Shown as a positive value despite being a cash outflow in the SEC filing.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.17B | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $1.10B | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | $1.10B | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | $1.09B | Feb 20, 2025 |
| FY2023 | Dec 31, 2021 | $1.03B | Feb 15, 2024 |
| FY2022 | Dec 31, 2020 | $975.00M | Feb 16, 2023 |
| FY2021 | Dec 31, 2019 | $924.00M | Feb 17, 2022 |
| FY2020 | Dec 31, 2018 | $842.00M | Feb 18, 2021 |
| FY2019 | Dec 31, 2017 | $803.00M | Feb 20, 2020 |
| FY2018 | Dec 31, 2016 | $763.00M | Feb 21, 2019 |